A Novel Approach Utilizing Organ Specific Age Proteomics
Key claim: Organ-specific plasma proteomic age signatures and p16INK4A T-cell expression pre- and post-adjuvant chemotherapy may reveal whether immune aging tracks multi-organ biological aging and identify patients at highest risk of chemo-related cardiac, neurologic, and functional late toxicities.
Abstract
This study compares changes in P16INK4A expression and plasma proteomic signatures of specific organ age pre- and post-chemotherapy in women treated with adjuvant chemotherapy for early-stage breast cancer. It aims to determine if biological and accelerated immune aging, assessed using T cells from peripheral blood, represents aging in different organs.
Patients receiving chemotherapy, especially adjuvant regimens that include anthracyclines and taxanes, often experience late development of cardiac toxicity, functional loss, and cognitive decline. Comparing baseline characteristics with organ aging before therapy might identify patients at the highest risk for chemotherapy complications. For example, this is clinically significant for patients whose therapy includes taxanes or other drugs known to cause peripheral neuropathy. Identifying aging in the neurological or vascular systems before treatment might lead to changes in regimens.
Determining accelerated aging in specific organs allows for investigating interventions to mitigate organ damage. For instance, identifying patients at the highest risk of cardiac aging after treatment could lead to testing the effects of exercise, senolytics, and other strategies to reduce the risk of long-term heart disease.
Why this matters
Aging biomarkers have mostly been validated against chronological age or all-cause mortality; adjuvant chemotherapy is a rare acute geroprotection-relevant stressor where an aging readout could plausibly predict a concrete downstream outcome (cardiac, neurologic, functional late toxicity). Coupling a senescence-cell-intrinsic marker (T-cell p16INK4A) with organ-specific proteomic clocks tests whether immune aging tracks multi-organ biological aging under a defined insult, rather than assuming they move together. If the pairing predicts toxicity, it converts senescence and proteomic-clock biology into a clinical stratification tool; if it doesn’t, it constrains how much these biomarkers actually capture organ-level vulnerability.